Zobrazeno 1 - 10
of 307
pro vyhledávání: '"John T, Schiller"'
Autor:
Jaimie Z. Shing, Carolina Porras, Maísa Pinheiro, Rolando Herrero, Allan Hildesheim, Danping Liu, Mitchell H. Gail, Byron Romero, John T. Schiller, Michael Zúñiga, Sambit Mishra, Laurie Burdette, Kristine Jones, John Schussler, Rebeca Ocampo, Jianwen Fang, Zhiwei Liu, Douglas R. Lowy, Sabrina H. Tsang, Ana Cecilia Rodríguez, Mark Schiffman, Cameron B. Haas, Loretto J. Carvajal, Jalen R. Brown, Aimée R. Kreimer, Lisa Mirabello, Costa Rica HPV Vaccine Trial (CVT) Group
Publikováno v:
npj Vaccines, Vol 9, Iss 1, Pp 1-11 (2024)
Abstract The AS04-adjuvanted human papillomavirus (HPV)16/18 vaccine, an L1-based vaccine, provides strong vaccine efficacy (VE) against vaccine-targeted type infections, and partial cross-protection to phylogenetically-related types, which may be af
Externí odkaz:
https://doaj.org/article/34f39d3bc9f746019ec00687f85c2a66
Autor:
Gathoni Kamuyu, Filomeno Coelho da Silva, Vanessa Tenet, John Schussler, Anna Godi, Rolando Herrero, Carolina Porras, Lisa Mirabello, John T. Schiller, Mónica S. Sierra, Aimée R. Kreimer, Gary M. Clifford, Simon Beddows
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-12 (2024)
Abstract Human Papillomavirus (HPV) type variants have been classified into lineages and sublineages based upon their whole genome sequence. Here we have examined the specificity of antibodies generated following natural infection with lineage varian
Externí odkaz:
https://doaj.org/article/91f73354b6cb4e45b787fce4d660d3f2
Autor:
Alexandra Fowler, Koen K. A. Van Rompay, Maureen Sampson, Javier Leo, Jennifer K. Watanabe, Jodie L. Usachenko, Ramya Immareddy, Debbie M. Lovato, John T. Schiller, Alan T. Remaley, Bryce Chackerian
Publikováno v:
npj Vaccines, Vol 8, Iss 1, Pp 1-11 (2023)
Abstract Elevated low-density lipoprotein cholesterol (LDL-C) is an important risk factor in the development of atherosclerotic cardiovascular disease (ASCVD). Inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9), a negative regulator
Externí odkaz:
https://doaj.org/article/facb55d5a57b495fafe7c6f7e035a99f
Autor:
Sabrina H. Tsang, John T. Schiller, Carolina Porras, Troy J. Kemp, Rolando Herrero, John Schussler, Monica S. Sierra, Bernal Cortes, Allan Hildesheim, Douglas R. Lowy, Ana Cecilia Rodríguez, Byron Romero, Nicolas Çuburu, Jaimie Z. Shing, Ligia A. Pinto, Joshua N. Sampson, Aimée R. Kreimer, on behalf of the Costa Rica HPV Vaccine Trial Group
Publikováno v:
npj Vaccines, Vol 7, Iss 1, Pp 1-9 (2022)
Abstract The HPV vaccine has shown sustained efficacy and consistent stabilization of antibody levels, even after a single dose. We defined the HPV16-VLP antibody avidity patterns over 11 years among women who received one- or three doses of the biva
Externí odkaz:
https://doaj.org/article/d8d0fcb1cc4f4e61b568dfc53679c2e8
Autor:
Kathy Baisley, MSc, Troy J Kemp, PhD, Aimée R Kreimer, PhD, Partha Basu, PhD, John Changalucha, MSc, Allan Hildesheim, PhD, Carolina Porras, MSc, Hilary Whitworth, PhD, Rolando Herrero, PhD, Charles J Lacey, MD, John T Schiller, PhD, Eric Lucas, MSc, Paul Mutani, MD, Joakim Dillner, PhD, Jackton Indangasi, MSc, Richard Muwonge, PhD, Richard J Hayes, DSc, Ligia A Pinto, PhD, Deborah Watson-Jones, PhD
Publikováno v:
The Lancet Global Health, Vol 10, Iss 10, Pp e1485-e1493 (2022)
Summary: Background: Human papillomavirus (HPV) vaccines are given as a two-dose schedule in children aged 9–14 years, or as three doses in older individuals. We compared antibody responses after one dose of HPV vaccine in the Dose Reduction Immuno
Externí odkaz:
https://doaj.org/article/bf9f94967e13494a8f7463ddd3a33ca7
Autor:
Rhonda C. Kines, John T. Schiller
Publikováno v:
Viruses, Vol 14, Iss 8, p 1656 (2022)
Human papillomaviruses (HPV) are small non-enveloped DNA tumor viruses established as the primary etiological agent for the development of cervical cancer. Decades of research have elucidated HPV’s primary attachment factor to be heparan sulfate pr
Externí odkaz:
https://doaj.org/article/0655f8d711ee4ea1b82dc0cbd6bb9996
Autor:
Meredith S. Shiels, Stanley Lipkowitz, Nicole G. Campos, Mark Schiffman, John T. Schiller, Neal D. Freedman, Amy Berrington de González
Publikováno v:
Cancer Discovery. 13:1084-1099
On February 2, 2022, President Biden and First Lady Dr. Biden reignited the Cancer Moonshot, setting a new goal to reduce age-standardized cancer mortality rates by at least 50% over the next 25 years in the United States. We estimated trends in U.S.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bf2185e5a7c5ce3ed7c9a3c65bbd5330
https://doi.org/10.1158/2159-8290.cd-23-0208
https://doi.org/10.1158/2159-8290.cd-23-0208
Autor:
Jaimie Z Shing, Shangying Hu, Rolando Herrero, Allan Hildesheim, Carolina Porras, Joshua N Sampson, John Schussler, John T Schiller, Douglas R Lowy, Mónica S Sierra, Loretto Carvajal, Aimée R Kreimer, Bernal Cortés, Paula González, Silvia E. Jiménez, Ana Cecilia Rodríguez, Aimée R. Kreimer, Douglas R. Lowy, Mark Schiffman, John T. Schiller, Mark Sherman, Sholom Wacholder, Ligia A. Pinto, Troy J. Kemp, Mary K. Sidawy, Wim Quint, Leen-Jan van Doorn, Linda Struijk, Joel M. Palefsky, Teresa M. Darragh, Mark H. Stoler
Publikováno v:
Lancet Oncol
In women vaccinated against human papillomavirus (HPV), reductions in cervical disease and related procedures results in more women having intact transformation zones, potentially increasing the risk of cervical lesions caused by non-vaccine-preventa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d36301a53f08f56e34541e998359597
https://doi.org/10.1016/s1470-2045(22)00291-1
https://doi.org/10.1016/s1470-2045(22)00291-1
Autor:
John T, Schiller, Douglas R, Lowy
Publikováno v:
Cell Host & Microbe. 31:137-140
Vaccines against cancer-causing microbes could potentially prevent 15% of cancers worldwide and thereby address global disparities in cancer control. To reach this potential, the established hepatitis B virus and human papillomavirus vaccines must be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b53aa6b82b2c673d8ae5fe4194f26c5a
https://doi.org/10.1016/j.chom.2022.10.016
https://doi.org/10.1016/j.chom.2022.10.016
Autor:
Holly J. Prudden, Sharon L. Achilles, Celina Schocken, Nathalie Broutet, Karen Canfell, Hiroki Akaba, Partha Basu, Neerja Bhatla, Z. Mike Chirenje, Sinead Delany-Moretlwe, Lynette Denny, Deepa G. Gamage, Rolando Herrero, Raymond Hutubessy, Luisa Lina Villa, Raul Murillo, John T. Schiller, Margaret Stanley, Marleen Temmerman, Fanghui Zhao, Gina Ogilvie, David C. Kaslow, Peter Dull, Sami L Gottlieb
Publikováno v:
Vaccine. 40:5843-5855
The World Health Organization (WHO) global strategy to eliminate cervical cancer (CxCa) could result ingt;62 million lives saved by 2120 if strategy targets are reached and maintained: 90% of adolescent girls receiving prophylactic human papillomavir
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::191113fbdf315debc73da5da93843572
https://doi.org/10.1016/j.vaccine.2022.08.020
https://doi.org/10.1016/j.vaccine.2022.08.020